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metrics were adjusted for patient compliance with OADs as
reported in the literature. These metrics are reported as adjusted
and unadjusted estimates for patient compliance over a three-
year time frame. RESULTS: In this scenario, market share for
pioglitazone plus glimepiride was assumed to increase from
0.04% (2006) to 0.36% (2007) to 0.50% (2008). Projected
annual treatment costs adjusted for compliance ranged from
$22,240 (2006) to $200,164 (2007) to $278,006 (2008). Unad-
justed estimates range from $35,295 (2006) to $317,652 (2007)
to $441,183 (2008). Projected PMPM costs adjusted for compli-
ance ranged from $0.002 (2006) to $0.017 (2007) to $0.023
(2008). Unadjusted PMPM estimates range from $0.003 (2006)
to $0.026 (2007) to $0.037 (2008). CONCLUSION: The budget
impact of adding pioglitazone plus glimepiride on formulary was
minimal over a three-year time frame in both scenarios. This is
driven by anticipated market projections estimating the utiliza-
tion of pioglitazone plus metformin among the class of OAD
agents.
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OBJECTIVE: There is a practically stable 5.3 % prevalence of
diabetes mellitus (DM) in Slovakia. The treatment ratio was as
follows: 47.6 % patients are on diet, 30.8 % on PAD and 21.6 %
on insulin. The main objective of this study was to determine if
the intensiﬁed insulin therapy with insulin pen is cost-effective
compared to conventional therapy. METHODS: Direct medical
an non direct costs were evaluated in retrospective randomized
study in patients with DM type 2. A group of 48 patients on
intensiﬁed insulin therapy (IIT) was compared with a group of 28
patients treated with conventional therapy (CT). RESULTS: The
average duration of DM was 113.51 months in IIT group and
147.67 months in CT group. The signiﬁcant difference
(p < 0.05,s) was observed in age (53.19 in IIT vs 55.11 in CT)
and in serum cholesterol (6.14 in ITT vs 6.65 in CT). The
hospital costs were higher in IIT: €568 vs. €511 in CT. The
laboratory costs were lower in IIT: €133 vs. €167 in CT. IIT had
higher costs for reimbursed drugs, glucometers and insulin pens
by Health Insurance Companies: €1065 vs. €1024 in CT. No
statistical difference was recorded in co-payments: €99 in IIT vs.
€100 in CT. Indirect patients costs based on time loss were €185
in IIT vs. €227 in CT. The total costs per patient per year were
€1972 in IIT vs. €1964 in CT. CONCLUSION: The treatment of
DM type 2 with insulin pen NovoPen® 3 is clinically and eco-
nomically effective in comparison to the treatment with syringe.
The estimated costs of LYS are €4759 in men and €6519 in
women per patient with DM in Slovakia.
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OBJECTIVE: To assess the impact of Apidra®, a new rapid-
acting insulin analog used in type 1 and 2 diabetes, on the health
care system in Poland. METHODS: Budget impact analysis has
been programmed using Microsoft Excel® 2003. Five-year
population-based model assumes that Apidra® will gain market
shares from rapid- and short acting insulins in proportion to their
original market shares distribution. Limit and reimbursement
rate of Apidra® was set equal to that of other rapid/short acting
insulins. In addition to the cost of insulins, the cost of blood
glucose monitoring strips was included in the total annual costs.
The perspective of: 1) public payer, 2) public payer + patient; was
considered separately. A range of compliance levels were also
taken into account. Sensitivity analysis (including the analysis of
extreme scenarios—most pessimistic and optimistic) was per-
formed to account for uncertainty in input parameters.
RESULTS: Financing Apidra® from public means will have no
consequences for a public payer, which results from equal limits
for all rapid- and short acting insulins. From the perspective of
both payers for health care services (NHF and patient), incre-
mental costs associated with introducing Apidra® to the market
increase from 642–1 018 PLN (0.0001–0.0002%) in year one to
20 307–32 226 PLN (0.0044–0.005%) in the 5th year post-
launch, depending on the drug compliance level assumed (230 or
365 days/year). Results were most sensitive to the change of
Apidra(r) price. CONCLUSION: Results of the analysis indicate
that decision to ﬁnance Apidra® from public means in Poland
would have no consequences for a public payer, and the impact
from the perspective of both payers (public payer and patient) is
not likely to be signiﬁcant.
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OBJECTIVE: Somatropin is human growth hormone (GH) pro-
duced by recombinant DNA technology. Several somatropin
products with unique delivery devices are available. When
administering the last dose from a device, patients may have an
insufﬁcient amount of GH remaining for a full dose. Based on a
survey of parents/patients using pen devices conducted at the
2007 MAGIC Foundation Convention, 63% of respondents
reported that they were likely to discard this remaining amount
left in the cartridge (i.e., waste). easypod, an electronic GH
delivery device for somatropin (rDNA origin) for injection (EMD
Serono, Inc.), contains a dose spread feature designed to mini-
mize waste. A model was developed to estimate potential GH
waste per patient with pen devices and the easypod device and
quantify the potential annual economic impact. METHODS:
Base case model utilizes a daily dose (2 mg) reﬂective of the
national mean for all GH pen devices (Wolters Kluwer, 2007). A
10% mechanical loss is applied uniformly across all devices
based on the reported mechanical loss in the prescribing infor-
mation for somatropin (rDNA origin) for injection (EMD
Serono, Inc.). Model assumes that the easypod dose spread func-
tion (10%;25%; or50%) is activated by the clinician (base
case utilizes25%). This function minimizes waste by automati-
cally adjusting the daily dose (+/-) to optimize the cartridge
content; the cumulative average of injected doses is equal to the
prescribed daily dose. Annual cost of GH waste per patient for
each device is reported (wholesale acquisition cost, Medispan,
2007). RESULTS: Expected annual cost of GH waste per patient
was lowest for easypod ($112). Results for pen devices ranged
from $794 to $3363 (using largest cartridge size for each
product). Results ﬂuctuate depending on daily dose, cartridge
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size and dose spread assumptions. CONCLUSION: Cost of GH
waste can be an important consideration when evaluating GH
devices.
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OBJECTIVE: The objective of this study was to compare RU and
costs for drug naïve patients treated with RSG versus SU ﬁrst-line
monotherapy using real-world claims data. METHODS: Based
on medical, pharmacy, and disability insurance claims data
between October 2001 and December 2004, patients with a
diagnosis T2D who were newly initiated on an OAD, 18 years
old, and had 60 days of uninterrupted treatment were ana-
lyzed. Frequency of inpatient and outpatient visits and average
direct (inpatient, outpatient, and pharmacy) and indirect (work-
loss) costs were compared between the RSG and SU groups.
RESULTS: A total of 3377 RSG and 11,778 SU patients met
the inclusion criteria with RSG patients being younger (63.8 vs.
66.9 years, p < 0.001) with less co-morbidities (Charlson
co-morbidity index 0.95 vs. 1.23, p < 0.001) at baseline. During
treatment, RSG patients incurred fewer inpatient visits (0.47 vs.
0.77 visits per patient per year (PPPY), p < 0.001), outpatient
visits (17.0 vs. 17.9 visits PPPY, p < 0.001), and hospital days
(1.6 vs. 2.9 days PPPY, p < 0.001) than SU patients. The total
direct medical cost was lower in the RSG group ($1065 vs.
$1315 per patient per month (PPPM), p < 0.001) than the SU
group, including lower inpatient and outpatient cost ($717 vs.
$1046 PPPM, p < 0.001) but higher pharmacy cost ($348 vs.
$270 PPPM, p < 0.001). After taking into account the indirect
work-loss cost, the total direct and indirect cost was signiﬁcantly
lower in the RSG group ($1103 vs. $1355 PPPM, p < 0.001).
Multivariate analysis controlling for age, gender, co-morbidities,
and other covariates conﬁrmed that the RSG group was associ-
ated with a signiﬁcantly lower total cost than the SU group (cost
difference: $92.75 PPPM, p = 0.012). CONCLUSION: This
observational study of over 15,000 patients initiated on ﬁrst-line
monotherapy shows that RSG patients incur signiﬁcantly lower
resource utilization and costs than SU patients, outweighing
higher pharmacy cost.
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OBJECTIVE: Current treatment options for short children born
small for gestational age (SGA) are limited; however, the growth
hormone somatropin (Norditropin) has been shown to normalise
height in childhood and adolescence compared to no treatment.
The aim of this study was to establish whether somatropin (Nor-
ditropin) was a cost-effective treatment option for short children
born SGA compared to no treatment. METHODS: A decision
tree model was used to calculate the relative costs and health
beneﬁts associated with somatropin (Norditropin) treatment vs
no treatment over the lifetime of short children born SGA. The
analysis was undertaken from a UK National Health Service
(NHS) perspective; unit costs (GBP; 2007) were sourced from
relevant UK health care providers. Clinical effectiveness data
were taken from a long-term, multi-centre, double-blind, ran-
domised clinical trial comparing the effects of somatropin (Nor-
ditropin) to no treatment. Utility data was derived from a recent
UK-based study which assessed the relationship between short
stature and HRQoL. Sensitivity analyses were conducted to
assess the degree of uncertainty surrounding the data. RESULTS:
Over a patient’s lifetime, somatropin (Norditropin) (0.033 mg/
kg/day) was associated with an additional 2.74 quality-adjusted
life years (QALYs) and an incremental cost of GBP73,545 com-
pared with no treatment. As a result, somatropin (Norditropin)
was associated with an incremental cost per QALY of
GBP26,794 compared with no treatment. Probabilistic sensitivity
analysis, in which all parameters within the model were varied,
showed that there was a high probability that somatropin
(Norditropin) was cost effective compared to no treatment, based
on a willingness to pay threshold of GBP30,000 per QALY.
CONCLUSION: Based on a willingness to pay threshold
of GBP30,000 per QALY, somatropin (Norditropin) is a cost-
effective treatment strategy for short children born SGA, provid-
ing substantial incremental health beneﬁts at an additional cost.
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OBJECTIVE: Insulin detemir represents a class of long-acting
soluble insulin analogues intended to address basal insulin
requirements for patients with diabetes. Because direct acquisi-
tion costs of newer medications are higher than older insulin
treatments, payers are interested in their long-term value. This
study was conducted to quantify the long-term cost-effectiveness
of insulin detemir compared to intermediate-acting NPH insulin
for the treatment of T1DM in Canada. METHODS: The CORE
Diabetes Model was used to project lifetime clinical and eco-
nomic outcomes for T1DM patients on insulin detemir versus
NPH insulin. A slight advantage for insulin detemir in HbA1c
(-0.12%) and signiﬁcant reductions in major (69%) and minor
(25%) hypoglycemic events were modeled. These clinical
assumptions, as well as cohort characteristics (baseline age and
HbA1c of 27 and 8.9%, respectively), transition probabilities,
utilities, dis-utilities, direct treatment and complication costs
(from a Canadian provincial payer perspective) were derived
from recent published literature and on-line sources. Both clinical
and economic outcomes were discounted at 5% per annum.
RESULTS: Average total direct costs per patient were
CAN$88,403 for insulin detemir and CAN$76,551 for NPH
using a lifetime horizon. A 61% reduction in major hypoglyce-
mic events costs for detemir (CAN$765) vs. NPH (CAN$1965)
were observed. Quality-adjusted life years (QALYs) increased by
0.344 years (discounted) with detemir and were largely due to
decreased hypoglycemic events. The resulting incremental cost-
effectiveness ratio (ICER) for detemir vs. NPH was
CAN$34,418/QALY. CONCLUSION: The ICER obtained in
this analysis provides evidence for the long-term cost-
effectiveness of insulin detemir compared to NPH in T1DM and
is consistent with current Canadian standards. The overall value
of detemir was driven primarily by its favorable impact upon
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